Berahyaluronidase alfa (MK-3475A)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Berahyaluronidase alfa (MK-3475A), covering 2025-11-12 to 2025-11-12. Get the full timeline:
Most recent: Clinical Trial Update: A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)-Japan Extension [Phase 3]